Consensus on the management of united airways disease with type 2 inflammation: a multidisciplinary Delphi study.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsMBA has received honoraria for lectures, courses, participation in monographs and standards, or scientific advice from AstraZeneca, Sanofi, Esteve, GSK, Menarini, Novartis, Chiesi, and TEVA. JDO has received funding for research and/or honoraria for consultancy and conferences from AstraZeneca, Chiesi, GSK, Bial, Novartis, Sanofi, and TEVA; and speaker fees from ALK, LETI Pharma, and Mundipharma. CCis has received financial aid from AstraZeneca, Chiesi, Novartis, Mundipharma, GSK, Pfizer, Menarini, and Sanofi for advisory services, papers, research studies, attendance at congresses or training courses. CCol has received honoraria for lectures, courses, participation in monographs and standards or scientific advice from AstraZeneca, Sanofi, GSK, Novartis, Viatris and Chiesi. FCM has received honoraria for lectures, courses, participation in monographs and standards or scientific advice from AstraZeneca, Chiesi, GSK, Novartis, Sanofi, and TEVA. AC reports grants and personal fees from MYLAN, FAES Pharma, Novartis, Allakos, and Sanofi; personal fees from ALK, GSK, MSD, AstraZeneca, and TEVA, outside the submitted work. IA has received honoraria for consultancy and conferences from Viatris, Sanofi, GSK, MSD, Menarini, GAES, Aural, and Novartis. SQ has received honoraria for consultancy and conferences from AstraZeneca, GSK and Sanofi, and speaker fees from Chiesi, Mundipharma, Novartis, and TEVA. JM is a member of national or international advisory boards and has received speaker fees or funding for clinical trials and research projects from Allakos, AstraZeneca, GSK, Menarini, Mitsubishi-Tanabe, MSD, Mylan-MEDA Pharma (Viatris), Novartis, Regeneron Pharmaceuticals, Sanofi, UCB Pharma, and Uriach Group. Competing interests MBA has received honoraria for lectures, courses, participation in monographs and standards, or scientific advice from AstraZeneca, Sanofi, Esteve, GSK, Menarini, Novartis, Chiesi, and TEVA. JDO has received funding for research and/or honoraria for consultancy and conferences from AstraZeneca, Chiesi, GSK, Bial, Novartis, Sanofi, and TEVA; and speaker fees from ALK, LETI Pharma, and Mundipharma. CCis has received financial aid from AstraZeneca, Chiesi, Novartis, Mundipharma, GSK, Pfizer, Menarini, and Sanofi for advisory services, papers, research studies, attendance at congresses or training courses. CCol has received honoraria for lectures, courses, participation in monographs and standards or scientific advice from AstraZeneca, Sanofi, GSK, Novartis, Viatris and Chiesi. FCM has received honoraria for lectures, courses, participation in monographs and standards or scientific advice from AstraZeneca, Chiesi, GSK, Novartis, Sanofi, and TEVA. AC reports grants and personal fees from MYLAN, FAES Pharma, Novartis, Allakos, and Sanofi; personal fees from ALK, GSK, MSD, AstraZeneca, and TEVA, outside the submitted work. IA has received honoraria for consultancy and conferences from Viatris, Sanofi, GSK, MSD, Menarini, GAES, Aural, and Novartis. SQ has received honoraria for consultancy and conferences from AstraZeneca, GSK and Sanofi, and speaker fees from Chiesi, Mundipharma, Novartis, and TEVA. JM is a member of national or international advisory boards and has received speaker fees or funding for clinical trials and research projects from Allakos, AstraZeneca, GSK, Menarini, Mitsubishi-Tanabe, MSD, Mylan-MEDA Pharma (Viatris), Novartis, Regeneron Pharmaceuticals, Sanofi, UCB Pharma, and Uriach Group."

"Funding This work was funded by Sanofi. Editorial assistance was provided by Celia Miguel-Blanco (Medical Science Consulting; Valencia, Spain). The authors were not compensated for writing the manuscript. The sponsor was not involved in the protocol design, data analysis, or manuscript writing."

"The Delphi questionnaire was drafted after a previously published systematic review that summarized recent evidence on the management of UAD (PROSPERO CRD42021262844) []. Briefly, a systematic literature search of international databases (PubMed, Web of Science, and Scopus) was conducted for articles published in English and Spanish from January 2015 to July 2021. The search strategy consisted of nine research questions that were defined using the PICO (P, patient; I, intervention; C, comparator; O, outcome) structure. Systematic reviews, clinical trials, post hoc studies, clinical practice guidelines, and observational studies reporting data on the management of T2 asthma and CRSwNP were included. In total, 32 publications were selected and assessed using the Critical Appraisal Skills Programme checklists []."